Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
14 hedge funds and large institutions have $8.66M invested in Avenue Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
17% more funds holding
Funds holding: 12 → 14 (+2)
1% more capital invested
Capital invested by funds: $8.59M → $8.66M (+$68K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$232K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$225K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$136K |
| 4 |
Squarepoint
New York
|
+$74.9K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$54.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$101K |
| 2 |
SIM
Spark Investment Management
New York
|
-$54.5K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $5.68M | +$136K | +20 | +2% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $819K | +$232K | +34 | +39% |
|
|
EI
3
EAM Investors
Solana Beach,
California
| $669K | +$225K | +33 | +49% |
|
|
BRWA
4
B. Riley Wealth Advisors
Boca Raton,
Florida
| $440K | +$54.5K | +8 | +14% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $404K | – | – | – |
|
6
BlackRock
New York
| $231K | – | – | – |
|
|
FWM
7
Frontier Wealth Management
Kansas City,
Missouri
| $119K | – | – | – |
|
|
SIM
8
Spark Investment Management
New York
| $87K | -$54.5K | -8 | -38% |
|
9
Northern Trust
Chicago,
Illinois
| $87K | – | – | – |
|
|
10
Squarepoint
New York
| $76K | +$74.9K | +11 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $28K | -$6.81K | -1 | -20% |
|
12
Victory Capital Management
San Antonio,
Texas
| $8K | +$6.81K | +1 | New |
|
13
Morgan Stanley
New York
| $7K | +$6.81K | +1 | New |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $4K | -$34K | -5 | -83% |
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
16
Renaissance Technologies
New York
| – | -$101K | -14 | Closed |
|
ATXI Hedge Fund Activity: Q3 2019 in Review
14 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2019, worth a combined $8.66M — up 0.79% from $8.59M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ATXI positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $232K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $101K sold.
- 14 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2019, up from 12 in Q2 2019.
- Funds reported $8.66M of Avenue Therapeutics, Inc. Common Stock stock for Q3 2019, up 0.79% quarter-over-quarter.
- 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +2 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $232K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2019 was Renaissance Technologies, an estimated $101K sold.
Based on aggregated 13F filings for Q3 2019.